Abstract
Qili qiangxin capsule (QL), a traditional Chinese herbal compound, has been proved to be effective and safe for the treatment of chronic heart failure (CHF). Upregulation of aquaporin-2 (AQP2) accounts for the water retention in CHF. The aim of the present study was to evaluate the effects of QL on the expression of AQP2 in rats with CHF induced by acute myocardial infarction and to investigate the underlying mechanisms. The urine output of all rats was quantified and collected every day at the first week and the 4th week after administration of QL or Valsartan. The expression of AQP2, vasopressin type 2 receptor (V2R), and angiotensin II type 1 receptor (AT1R) were examined after treatment for 4 weeks. Urinary output increased significantly after administration of QL. Importantly, the protein expression of AQP2 and AQP2 phosphorylated at serine 256 (pS256-AQP2) was downregulated after administration of QL and Valsartan to CHF rats. Furthermore, QL reduced plasma arginine vasopressin (AVP) and angiotensin II (AngII) level and downregulated V2R and AT1R protein expression. Thus, QL exerts its diuretic effect and improves cardiac function in CHF rats by reversing the increases in both AQP2 and pS256-AQP2 expression. The possible mechanisms may involve inhibition of V2R and AT1R.
Highlights
Chronic heart failure (CHF) is recognized as a major and escalating public health problem
To determine whether qiangxin capsule (QL) could alter the expression of renal vasopressin type 2 receptor (V2R), we examined V2R protein expression in medulla at 4 weeks after treatment
We found that CHF rats expressed higher levels of renal V2R than sham rats
Summary
Chronic heart failure (CHF) is recognized as a major and escalating public health problem. The prevalence of CHF is 12% and appears to be increasing, in part because of ageing of the population [1]. It has an annual hospitalisation rate of 2% with subsequent 1-year mortality of 30% [2]. CHF has become a major public health burden in the world that is associated with high morbidity, mortality, and cost [3, 4]. Improving congestion is a cornerstone of HF management. Loop diuretics are among the most commonly prescribed drugs in this setting, there are some adverse drug reactions associated with their use. Novel and safe therapeutic approaches for the treatment of congestion have been of interest in recent research
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
